Halozyme Therapeutics, Inc. held its Annual Meeting on May 5, 2026, where stockholders elected two Class I directors and approved executive compensation and Ernst & Young as auditors for 2026. Out of 118,474,300 outstanding shares, 104,138,244 were represented in the votes.